<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Probiotix Health Plc — News on 6ix</title>
    <link>https://6ix.com/company/probiotix-health-plc</link>
    <description>Latest news and press releases for Probiotix Health Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 30 Mar 2026 06:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/probiotix-health-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5852fbeedb30cb6f8ba4e.webp</url>
      <title>Probiotix Health Plc</title>
      <link>https://6ix.com/company/probiotix-health-plc</link>
    </image>
    <item>
      <title>Final Results and Investor Presentation</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/final-results-and-investor-presentation-8</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/final-results-and-investor-presentation-8</guid>
      <pubDate>Mon, 30 Mar 2026 06:00:00 GMT</pubDate>
      <description>Probiotix Health PLC reported a significant increase in sales for the year ended December 31, 2025, reaching £2.73 million, a 45% rise from £1.88 million in 2024, with gross profit also growing by 46% to £1.48 million. The company successfully reduced its EBITDA loss from continuing operations by 34% to £426,000, while improving its gross profit margin to 54%. Probiotix Health ended the year with a cash balance of £1.27 million and remains fully funded, having launched ten new products during th</description>
    </item>
    <item>
      <title>Notice of Results and Investor Presentation</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/notice-of-results-and-investor-presentation-170</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/notice-of-results-and-investor-presentation-170</guid>
      <pubDate>Mon, 16 Mar 2026 07:00:00 GMT</pubDate>
      <description>ProBiotix Health plc has announced that its audited results for the year ended 31 December 2025 will be released on Monday, 30 March 2026. The company&apos;s Chief Executive and Chief Finance Officer will present these results via Investor Meet Company on the same day at 10:00 BST, offering an opportunity for existing and potential shareholders to ask questions.
                Disclaimer*</description>
    </item>
    <item>
      <title>PDMR Shareholding</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/pdmr-shareholding-72</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/pdmr-shareholding-72</guid>
      <pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
      <description>ProBiotix Health plc announced that Michael Litichevski, Vice President of Sales, acquired 45,100 ordinary shares of 0.05p each at a price of 6.5p per share on February 16, 2026, on the Aquis Growth Market. This transaction represents an initial notification of a PDMR shareholding.
                Disclaimer*</description>
    </item>
    <item>
      <title>Statement re Share Price Movement</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/statement-re-share-price-movement-32</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/statement-re-share-price-movement-32</guid>
      <pubDate>Mon, 16 Feb 2026 12:30:00 GMT</pubDate>
      <description>ProBiotix Health plc notes a recent fall in its share price and states there are no fundamental commercial or operational reasons for this movement, believing it may stem from mistaken assumptions regarding events at SkinBioTherapeutics plc. While both companies were originally formed by OptiBiotix Health plc, which remains a significant shareholder in both, ProBiotix confirms there are no other commercial or operational links and that recent events at SkinBioTherapeutics have no bearing on its </description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/holdings-in-company-1302</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/holdings-in-company-1302</guid>
      <pubDate>Thu, 05 Feb 2026 17:00:00 GMT</pubDate>
      <description>ProBiotix Health plc announced that SENECA PARTNERS LIMITED, through its nominees PLATFORM SECURITIES NOMINEES LIMITED and WOODSIDE NOMINEES LIMITED, has reduced its shareholding to 4.9976%, representing 7,904,583 voting rights. This decrease from a previous holding of 6.6% is attributed to an orderly sell-down over several years and dilution from capital increases, with the 5% threshold being crossed on February 4, 2026.
                Disclaimer*</description>
    </item>
    <item>
      <title>Director/PDMR Shareholding</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/directorpdmr-shareholding-1159</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/directorpdmr-shareholding-1159</guid>
      <pubDate>Wed, 04 Feb 2026 07:00:00 GMT</pubDate>
      <description>ProBiotix Health plc announced that its Chairman, Adam Reynolds, acquired 150,000 ordinary shares at 8p per share, costing £12,000. Following this transaction on February 3, 2026, Mr. Reynolds now holds 442,857 ordinary shares, representing 0.28% of the Company&apos;s issued share capital. This director&apos;s purchase of shares at a price of 8p per share indicates confidence in the company&apos;s prospects.
                Disclaimer*</description>
    </item>
    <item>
      <title>Trading Update</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/trading-update-852</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/trading-update-852</guid>
      <pubDate>Wed, 21 Jan 2026 07:00:00 GMT</pubDate>
      <description>ProBiotix Health plc reported a strong trading performance for the year ended 31 December 2025, with sales increasing by 45% to £2.72 million and gross profit rising by 46% to £1.46 million, leading to a gross profit margin of 54%. The company significantly reduced its EBITDA loss from continuing operations by 31% to £445,000, while maintaining a healthy cash balance of £1.27 million. The first quarter of 2026 shows considerable promise with an order book up 110% to £1.3 million, driven by new c</description>
    </item>
    <item>
      <title>Move from Access to Apex Segment of Aquis</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/move-from-access-to-apex-segment-of-aquis</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/move-from-access-to-apex-segment-of-aquis</guid>
      <pubDate>Mon, 03 Nov 2025 07:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC announced that it has met the eligibility criteria to join the Apex segment of the Aquis Stock Exchange Growth Market. Trading on the Apex segment for the company&apos;s ordinary shares will commence on Monday, November 10, 2025. The Apex segment is designed for larger, more established businesses and includes additional eligibility criteria to promote greater transparency and liquidity. The company believes this transition validates its maturity and commercial achievements.

   </description>
    </item>
    <item>
      <title>Appointment of Aquis Corporate Adviser</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/appointment-of-aquis-corporate-adviser-5</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/appointment-of-aquis-corporate-adviser-5</guid>
      <pubDate>Thu, 23 Oct 2025 06:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC announced the appointment of AlbR Capital Limited as its Aquis Corporate Adviser, effective immediately on October 23, 2025. The company, which focuses on developing probiotics to support cardiometabolic health, is listed on AQSE under the ticker PBX. This appointment is intended to bolster ProBiotix&apos;s corporate advisory resources as it continues its work in microbiome modulating probiotics.

                Disclaimer*</description>
    </item>
    <item>
      <title>New Commercial Partnership in Australia</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/new-commercial-partnership-in-australia</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/new-commercial-partnership-in-australia</guid>
      <pubDate>Mon, 20 Oct 2025 06:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC has entered a commercial partnership with Wellizen, an Australian wellness brand company, to supply LPLDL® for local manufacturing of a new dietary supplement, Tri-Biotic Cardi-Flo, under the THERONOMIC® brand. The product targets cardiometabolic health and will initially launch in Singapore this October via Wellizen&apos;s e-commerce platform, followed by an Australian launch later in October. Expansion into New Zealand, Southeast Asia, and other Asian markets is planned, with p</description>
    </item>
    <item>
      <title>New Commercial Partnership in Sweden</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/new-commercial-partnership-in-sweden</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/new-commercial-partnership-in-sweden</guid>
      <pubDate>Tue, 14 Oct 2025 06:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC announced a commercial partnership with RevivaBio, a Swedish health company, to launch a new cholesterol-lowering product. The product will feature ProBiotix&apos;s patented probiotic strain LPLDL®. RevivaBio&apos;s new capsule dietary supplement will be introduced and launched in Sweden and several APAC markets during Q1 2026 under RevivaBio&apos;s brand, distributed through health stores and e-commerce. ProBiotix will manufacture the primary finished capsules, while RevivaBio will handle</description>
    </item>
    <item>
      <title>Q3 2025 Trading Update and Grant of Options</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/q3-2025-trading-update-and-grant-of-options</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/q3-2025-trading-update-and-grant-of-options</guid>
      <pubDate>Mon, 13 Oct 2025 06:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC announced a Q3 2025 trading update showing continued strong progress. Sales increased by 30% to £1.97 million, up from £1.52 million in 2024. Gross profit rose by 21% to £1.06 million compared to £874k in the previous year, although the gross profit margin decreased to 54% from 58% due to a small stock write down. The company&apos;s forward order book is at record levels. Additionally, the board issued 700,000 options to senior management, exercisable at 9.5p per share, with a 10</description>
    </item>
    <item>
      <title>Unaudited Interim Results to 30 June 2025</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/unaudited-interim-results-to-30-june-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/unaudited-interim-results-to-30-june-2025</guid>
      <pubDate>Mon, 08 Sep 2025 06:00:00 GMT</pubDate>
      <description>ProBiotix Health PLC reported unaudited interim results for the six months ending June 30, 2025, featuring a 33% increase in gross revenue to £1.34 million, up from £1.01 million in H1 2024. Gross profit also increased by 33% to £748,000, compared to £564,000 in the prior year. The company reduced its EBITDA loss, excluding share-based payments, by 52% to £112,000 from a £232,000 loss in H1 2024. Sales outside the USA grew significantly, increasing by 127% to £584,000 from £257,000. ProBiotix al</description>
    </item>
    <item>
      <title>Trading Update and Notice of Results</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/trading-update-and-notice-of-results-138</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/trading-update-and-notice-of-results-138</guid>
      <pubDate>Tue, 15 Jul 2025 06:00:00 GMT</pubDate>
      <description>Trading Update and Notice of Results.</description>
    </item>
    <item>
      <title>Result of AGM and Notice of Trading Update</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/result-of-agm-and-notice-of-trading-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/result-of-agm-and-notice-of-trading-update-1</guid>
      <pubDate>Fri, 27 Jun 2025 11:35:00 GMT</pubDate>
      <description>Result of AGM and Notice of Trading Update.</description>
    </item>
    <item>
      <title>Notice of Annual General Meeting - Clarification</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/notice-of-annual-general-meeting-clarification</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/notice-of-annual-general-meeting-clarification</guid>
      <pubDate>Thu, 05 Jun 2025 16:30:00 GMT</pubDate>
      <description>Notice of Annual General Meeting - Clarification.</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/notice-of-agm-665</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/notice-of-agm-665</guid>
      <pubDate>Fri, 30 May 2025 06:00:00 GMT</pubDate>
      <description>Notice of AGM.</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/final-results-780</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/final-results-780</guid>
      <pubDate>Thu, 29 May 2025 06:00:00 GMT</pubDate>
      <description>Final Results.</description>
    </item>
    <item>
      <title>New Partnership Agreement in South Korea</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/new-partnership-agreement-in-south-korea</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/new-partnership-agreement-in-south-korea</guid>
      <pubDate>Fri, 28 Mar 2025 07:00:00 GMT</pubDate>
      <description>New Partnership Agreement in South Korea.</description>
    </item>
    <item>
      <title>Grant of Options</title>
      <link>https://6ix.com/company/probiotix-health-plc/news/grant-of-options-211</link>
      <guid isPermaLink="true">https://6ix.com/company/probiotix-health-plc/news/grant-of-options-211</guid>
      <pubDate>Thu, 20 Feb 2025 07:01:00 GMT</pubDate>
      <description>Grant of Options.</description>
    </item>
  </channel>
</rss>